A short seller report from Culper Research accused ADMA Biologics (ADMA) of channel stuffing and inflating revenue growth, followed by multiple law firms launching securities law investigations and a sharp one day share price drop.

Against this backdrop of short seller allegations and legal investigations, ADMA Biologics’ recent 1-day share price return of 6.16% and 7-day share price return of 7.90% follow a much weaker 30-day share price return of 37.82% and year to date share price return of 45.02%. The 3 year total shareholder return is more than 3x despite a 1 year total shareholder return decline of 49.30%, suggesting long term holders have seen substantial gains but short term momentum has faded.

If this kind of volatility has you looking beyond a single biotech name, it could be a moment to scan for other opportunities through 34 healthcare AI stocks

With allegations, legal probes, and a sharp pullback already on the table, today’s US$9.83 share price and very large discount to analyst targets raise the key question: is ADMA Biologics now undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 53% Undervalued

According to the most followed valuation narrative, ADMA Biologics’ fair value of $20.93 sits well above the recent $9.83 share price, creating a wide gap for investors to assess.

I assume ADMA can generate 1 BUSD in revenues by 2029 (S29) with FCF margin 35% (FCF29 = 350 MUSD) and net profit margin of 30% (E29 = 300 MUSD)

To be conservative let me assume lower multiples for ADMA in 2029 than CSL currently has, although ADMA may still have a higher growth rate than CSL currently has

The valuation story is built on strong revenue expansion, high margins, and a future earnings multiple that resembles a mature leader rather than an early stage biotech. It raises questions about which specific growth and profitability assumptions support that US$20 fair value estimate and how sensitive the narrative might be to even small changes in those inputs.

Result: Fair Value of $20.93 (UNDERVALUED)

However, this hinges on ADMA delivering on aggressive revenue, margin and yield assumptions, while short seller claims or legal outcomes could still weigh on sentiment and valuation multiples.

Next Steps

With sentiment divided between sharp concerns and a strong undervaluation narrative, it can be useful to act promptly and evaluate the key data points yourself using 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If ADMA’s story has you thinking bigger, do not sit on the sidelines. While others scan for alternatives, broaden your watchlist now using these targeted stock idea lists.

• Target potential mispricings early by reviewing 64 high quality undervalued stocks that combine attractive pricing with solid underlying fundamentals.
• Prioritize resilience by focusing on 72 resilient stocks with low risk scores that score well on financial strength and business stability.
• Get ahead of the crowd by tracking the screener containing 24 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.